ASCO Gastrointestinal Cancers Symposium

Tevimbra Plus Chemotherapy May Improve Survival in First-Line ESCC

February 1st 2025, 3:00pm

Article

Early and late responders with esophageal squamous cell carcinoma experienced comparable OS benefits with Tevimbra plus chemo in the RATIONALE-306 trial.

Herceptin Combo Shows Limited Benefit in Gastric/GEJ Cancer

January 30th 2025, 7:43pm

Article

In the INNOVATION trial, adding Herceptin and Perjeta to chemotherapy increased toxicity in patients with HER2-positive gastric cancers.

Opdivo Plus Yervoy Improves Outcomes in Metastatic Colorectal Cancer Subset

January 29th 2025, 8:00pm

Article

The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic colorectal cancer.

Palliative Care May Improve Quality of Life in Esophageal Cancer

January 27th 2025, 10:00pm

Article

End-of-life palliative care consultations may also ease financial strain for patients with esophageal cancer.

Oral Liporaxel May Be Superior To Intravenous in Advanced Gastric Cancer

January 27th 2025, 4:14pm

Article

Among those with advanced gastric cancer, oral Liporaxel showed superior overall survival outcomes versus IV Liporaxel as a second-line therapy.

Study Shows Poor Outcomes in BRAF V600E-Mutant Metastatic CRC

January 26th 2025, 7:00pm

Article

Synchronous metastases did not affect survival in resected BRAF V600E-mutated metastatic colorectal cancer.

The BREAKWATER Trial Explores Braftovi, Erbitux and Chemo in BRAF V600E+ mCRC

January 26th 2025, 3:00pm

Video

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ metastatic colorectal cancer.

Neoadjuvant Keytruda Shows Significant Benefit in dMMR Colon Cancer

January 25th 2025, 8:30pm

Article

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete response rate of 44%.

ctDNA Status May Predict Disease-Free Survival With Celebrex in Colon Cancer

January 25th 2025, 7:58pm

Article

Although ctDNA positivity generally meant worse disease-free survival in stage 3 resected colon cancer, patients with ctDNA who received Celebrex had significantly better rates versus placebo.

Afinitor Plus Somatuline May Improve Survival in Aggressive GEP-NETs

January 25th 2025, 7:36pm

Video

Dr. Susumu Hijioka spoke about the benefit of this combination therapy in patients with unresectable or recurrent GEP-NETs, particularly those with high Ki-67 scores.